Kis, Janos T;
Seufert, Jochen;
Haluzik, Martin;
Bonnemaire, Mireille;
Vera, Carine;
Tournay, Mathilde;
Freemantle, Nick;
(2024)
Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI.
Diabetes Therapy
10.1007/s13300-024-01644-0.
(In press).
Preview |
Text
Freemantle_s13300-024-01644-0.pdf Download (800kB) | Preview |
Abstract
Introduction: This study aimed to evaluate the effect of baseline body mass index (BMI) and glycated hemoglobin (HbA1c) on the effectiveness and safety of initiating iGlarLixi (insulin glargine 100 U/ml and lixisenatide) in people with type 2 diabetes (T2D) in routine clinical practice. Methods: We pooled patient-level data from 1406 people with inadequately controlled T2D, initiating a 24-week iGlarLixi treatment. Analysis sets were based on baseline BMI and HbA1c. In the BMI set, 894 (64%) people had a BMI ≥30 kg/m2 and 510 (36%) a BMI<30 kg/ m2; in the HbA1c set, 615 (44%) people had an HbA1c >9%, 491 (35%) between 8 and 9%, and 298 (21%)<8%. Results: After initiating iGlarLixi, HbA1c decreased in all participants, with the greatest least-squares mean reduction at 2.15% from baseline to week 24 in those with baseline HbA1c>9% (using a mixed model for repeated measures). Overall, mean ± standard deviation body weight decreased by 1.9±4.8 kg, with the most prominent loss of 2.6±4.9 kg recorded in people presenting with obesity. Reported hypoglycemia rates were low across all groups. Conclusions: Initiation of iGlarLixi in people with uncontrolled T2D is effective and safe in clinical practice, across different baseline HbA1c and BMI categories.
| Type: | Article |
|---|---|
| Title: | Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s13300-024-01644-0 |
| Publisher version: | http://dx.doi.org/10.1007/s13300-024-01644-0 |
| Language: | English |
| Additional information: | Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, BMI, Fixed-ratio combination, HbA1c, iGlarLixi, Pooled analysis, Type 2 diabetes, FIXED-RATIO COMBINATION, PLUS LIXISENATIDE, LIXILAN, ASSOCIATION |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > Comprehensive CTU at UCL |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10198044 |
Archive Staff Only
 |
View Item |
